Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

被引：5

作者：

Vinti, Luciana ^{[1
]}

Pagliara, Daria ^{[1
]}

Buffardi, Salvatore ^{[2
]}

Di Ruscio, Valentina ^{[1
]}

Stocchi, Francesca ^{[1
]}

Mariggio, Elena ^{[1
]}

Parasole, Rosanna ^{[2
]}

Di Matteo, Antonia ^{[2
]}

Petruzziello, Fara ^{[2
]}

Paganelli, Valeria ^{[1
]}

De Vito, Rita ^{[3
]}

Del Bufalo, Francesca ^{[1
]}

Strocchio, Luisa ^{[1
]}

Locatelli, Franco ^{[1
,4
]}

机构：

[1] IRCCS, Dept Paediat Haematol Oncol Cell & Gene Therapy, Bambino Gesu Childrens Hosp, Piazza S Onofrio 4, I-00165 Rome, Italy

[2] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematol Oncol, Naples, Italy

[3] IRCCS, Dept Pathol, Bambino Gesu Childrens Hosp, Rome, Italy

[4] Univ Rome, Dept Pediat, Sapienza, Rome, Italy

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 04期

关键词：

brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse; STEM-CELL TRANSPLANTATION; PHASE-II; CHILDREN; THERAPY; MULTICENTER; GEMCITABINE; VINORELBINE; RECURRENT; EFFICACY; CANCER;

D O I：

10.1002/pbc.29557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.

引用

页数：9

共 50 条

[41] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: SINGLE CENTER EXPERIENCE
Valiev, Timur
Tsaplina, Nataly
Kirgizov, Kirill
PEDIATRIC BLOOD & CANCER, 2022, 69 : S589 - S589
[42] Importance of consolidation in patients with relapsed/refractory Hodgkin's lymphoma responders to Brentuximab Vedotin
Machet, Antoine
Cayssials, Emilie
Leleu, Xavier
Guidez, Stephanie
HEMATOLOGIE, 2016, 22 (04): : 248 - +
[43] Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin
Faulk, Kelly E.
Sopfe, Jenna M.
Campbell, Kristen
Liptzin, Deborah R.
Liu, Arthur K.
Franklin, Anna R. K.
Cost, Carrye R.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 251 - 256
[44] COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA
Khachatryan, G. R.
Fedyaev, D.
Avxentyeva, M.
Dombrovskiy, V. S.
VALUE IN HEALTH, 2016, 19 (07) : A734 - A734
[45] Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children's Oncology Group report
Cole, Peter D.
Metzger, Monika
Drachtman, Richard A.
Horton, Terzah M.
Liu, Xiaowei
Ahern, Charlotte H.
Minard, Charles
Fox, Elizabeth
Blaney, Susan
Weigel, Brenda
Kelly, Kara M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[46] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
Tsirigotis, P.
Vassilakopoulos, T.
Bousiou, Z.
Mpatsis, I.
Gkirkas, K.
Sakellari, I.
Papageorgiou, S.
Roussou, P.
Pangalis, G.
Galani, Z.
Moschoyianni, M.
Vassilopoulos, G.
Repoussis, P.
Megalakaki, E.
Michalis, E.
Anagnostopoulos, N.
Calpadaki, C.
Papadaki, H.
Margaritis, D.
Chatzimichail, E.
Briassoulis, E.
Spyridonidis, A.
Grentzelias, D.
Anargyrou, K.
Tsionos, K.
Mpanti, A.
Poulakidas, E.
Palaska, C.
Gribabi, D.
Apostolidis, J.
Pappa, V.
Harhalakis, N.
Panayiotidis, P.
Konstantopoulos, K.
Anagnostopoulos, A.
Angelopoulou, M.
HAEMATOLOGICA, 2015, 100 : 454 - 455
[47] Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)
Czyz, Anna
Lojko-Dankowska, Anna
Joks, Monika
Komarnicki, Mieczyslaw
Dlugosz-Danecka, Monika
Jurczak, Wojciech
Rybka, Justyna
Wrobel, Tomasz
Paszkiewicz, Ewa
Walewski, Jan
Hawrylecka, Dorota
Drozd-Sokolowska, Joanna
Subocz, Edyta
Agata, Szymanska
Witkowska, Magdalena
Smolewski, Piotr
Kolkowska, Agnieszka
Maranda, Ewa Lech
Knopinska-Posluszny, Wanda
Giebel, Sebastian
Zaucha, Jan
BLOOD, 2018, 132
[48] Nivolumab plus Brentuximab vedotin plus /- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
Greve, Patrick
Beishuizen, Auke
Hagleitner, Melanie
Loeffen, Jan
Veening, Margreet
Boes, Marianne
Peperzak, Victor
Diez, Claudius
Meyer-Wentrup, Friederike
FRONTIERS IN IMMUNOLOGY, 2023, 14
[49] Brentuximab Vedotin and Bendamustine Combination Therapy as Salvage for Relapsed-Refractory Hodgkin Lymphoma: A Real-World Single-Center Experience
Bajaj, Rajat
Radhakrishnan, Vivek
Bhave, Saurabh
Kumar, Jeevan
Arora, Neeraj
Dey, Debdeep
Parihar, Mayur
Mishra, Deepak
Chandy, Mammen
Nair, Reena
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S246 - S247
[50] Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
Harker-Murray, Paul
Mauz-Koerholz, Christine
Leblanc, Thierry
Mascarin, Maurizio
Michel, Gerard
Cooper, Stacy
Beishuizen, Auke
Leger, Kasey J.
Amoroso, Loredana
Buffardi, Salvatore
Rigaud, Charlotte
Hoppe, Bradford S.
Lisano, Julie
Francis, Stephen
Sacchi, Mariana
Cole, Peter D.
Drachtman, Richard A.
Kelly, Kara M.
Daw, Stephen
BLOOD, 2023, 141 (17) : 2075 - 2084

← 1 2 3 4 5 →